HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 10-05-2005, 04:38 PM   #1
Rich
Guest
 
Posts: n/a
Aromasin approved for adjuvant use

New Indication Offers Breast Cancer Patients
an Advanced Treatment Regimen

NEW YORK, Oct. 5 /PRNewswire-FirstCall/ -- Pfizer Inc said today that it
has received approval from the U.S. Food and Drug Administration (FDA) to
market Aromasin(R) (exemestane tablets) for adjuvant treatment of
postmenopausal women with estrogen-receptor positive early breast cancer
following two-to-three years of tamoxifen for a completion of five consecutive
years of adjuvant hormonal therapy.
The approval was based on the Intergroup Exemestane Study (IES) which
showed that patients who switched to Aromasin after two-to-three years of
tamoxifen, for a combined total of five years of therapy, had 31 percent more
protection from cancer recurrence than those who remained on five years of
tamoxifen therapy.
This landmark study, published in the New England Journal of Medicine,
established the superiority of switching to Aromasin rather than remaining on
tamoxifen. Following its publication, the American Society of Clinical
Oncologists and the National Comprehensive Cancer Network updated their
guidelines to support the use of a new switch regimen using Aromasin adjuvant
treatment.
"Pfizer is pleased to announce this treatment advance," said Dr. Joseph
Feczko, Pfizer's chief medical officer. "This new indication for Aromasin
provides women with a new treatment regimen that can significantly improve
their chances of remaining breast cancer-free."
The IES trial involved over 4,700 postmenopausal women with estrogen-
receptor positive breast cancer who were followed for an average of 35 months.
Patients receiving Aromasin experienced a significant reduction in the risk
for recurrence of the disease, compared to those continuing on tamoxifen.
This reduction includes fewer local and distant tumors as well as new cancers
in the other breast.
"This new approval for Aromasin clearly provides physicians and patients a
more effective way of protecting against cancer recurrence compared to the
current treatment practice of five years of tamoxifen therapy," said Dr.
Stephen Jones, medical director at U.S. Oncology Research in Houston, Texas.
The most common side effects for Aromasin, which were mild-to-moderate,
include hot flashes (21.2%), fatigue (16.1%) and arthalgia/ bone pain (14.6%).
Aromasin should not be administered to pre-menopausal women and women who
are pregnant. Dose modifications should be considered for patients taking
concomitant CYP3A4 inducers.
Breast cancer is one of the most common cancers occurring in women and the
second leading cause of death from cancer in women, after lung cancer.
Adjuvant therapy is treatment given following surgical removal of a primary
tumor (the first tumor that occurs before it spreads to other parts of the
body).
Last month, Pfizer received approval for adjuvant treatment in the
European Union. Aromasin was approved in the United States late in 1999 for
the treatment of advanced breast cancer in postmenopausal women whose tumors
have stopped responding to tamoxifen. It also is approved for use in Europe,
Japan, and South America. Currently, Aromasin is available in more than 50
countries around the globe.
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 03:02 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter